Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in HSV-2 seropositive women.

Richert-Spuhler LE, Pattacini L, Plews M, Irungu E, Muwonge TR, Katabira E, Mugo N, Meyers AFA, Celum C, Baeten JM, Lingappa JR, Lund JM.

AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002323. [Epub ahead of print]

PMID:
31335802
2.

A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.

Patel RC, Stalter RM, Thomas KK, Tamraz B, Blue SW, Erikson DW, Kim CJ, Kelley EJ, Nanda K, Kourtis AP, Lingappa JR, Mugo N, Baeten JM, Scarsi KK; Partners PrEP Study Team.

AIDS. 2019 Jul 10. doi: 10.1097/QAD.0000000000002308. [Epub ahead of print]

PMID:
31306173
3.

Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission.

Williams-Wietzikoski CA, Campbell MS, Payant R, Lam A, Zhao H, Huang H, Wald A, Stevens W, Gray G, Farquhar C, Rees H, Celum C, Mullins JI, Lingappa JR, Frenkel LM.

J Virol. 2019 Jun 14;93(13). pii: e01769-18. doi: 10.1128/JVI.01769-18. Print 2019 Jul 1.

PMID:
30996101
4.

Correction: Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2019 Feb 11;15(2):e1007588. doi: 10.1371/journal.ppat.1007588. eCollection 2019 Feb.

5.

HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.

Heffron R, Stalter R, Pyra M, Nanda K, Erikson DW, Hladik F, Blue SW, Davis NL, Mugo N, Kourtis AP, Lingappa JR, Baeten JM; Partners PrEP Study and Partners in Prevention HSV/HIV Transmission Study Teams.

AIDS. 2019 Mar 15;33(4):735-744. doi: 10.1097/QAD.0000000000002123.

PMID:
30585845
6.

Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.

Ebrahimi D, Richards CM, Carpenter MA, Wang J, Ikeda T, Becker JT, Cheng AZ, McCann JL, Shaban NM, Salamango DJ, Starrett GJ, Lingappa JR, Yong J, Brown WL, Harris RS.

Nat Commun. 2018 Oct 8;9(1):4137. doi: 10.1038/s41467-018-06594-3.

7.

Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing.

Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, Shah MP, Richie MB, Gorman MP, Hajj-Ali RA, Calabrese LH, Zorn KC, Chow ED, Greenlee JE, Blum JH, Green G, Khan LM, Banerji D, Langelier C, Bryson-Cahn C, Harrington W, Lingappa JR, Shanbhag NM, Green AJ, Brew BJ, Soldatos A, Strnad L, Doernberg SB, Jay CA, Douglas V, Josephson SA, DeRisi JL.

JAMA Neurol. 2018 Aug 1;75(8):947-955. doi: 10.1001/jamaneurol.2018.0463.

8.

Identifying the assembly intermediate in which Gag first associates with unspliced HIV-1 RNA suggests a novel model for HIV-1 RNA packaging.

Barajas BC, Tanaka M, Robinson BA, Phuong DJ, Chutiraka K, Reed JC, Lingappa JR.

PLoS Pathog. 2018 Apr 17;14(4):e1006977. doi: 10.1371/journal.ppat.1006977. eCollection 2018 Apr.

9.

Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.

Reed JC, Westergreen N, Barajas BC, Ressler DTB, Phuong DJ, Swain JV, Lingappa VR, Lingappa JR.

J Virol. 2018 Apr 13;92(9). pii: e01761-17. doi: 10.1128/JVI.01761-17. Print 2018 May 1.

10.

Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women.

Pyra M, Lingappa JR, Heffron R, Erikson DW, Blue SW, Patel RC, Nanda K, Rees H, Mugo NR, Davis NL, Kourtis AP, Baeten JM; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams.

Contraception. 2018 Apr;97(4):357-362. doi: 10.1016/j.contraception.2018.01.011. Epub 2018 Feb 17.

11.

Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS/MS.

Blue SW, Winchell AJ, Kaucher AV, Lieberman RA, Gilles CT, Pyra MN, Heffron R, Hou X, Coombs RW, Nanda K, Davis NL, Kourtis AP, Herbeck JT, Baeten JM, Lingappa JR, Erikson DW.

Contraception. 2018 Apr;97(4):363-369. doi: 10.1016/j.contraception.2018.01.015. Epub 2018 Jan 31.

12.

Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.

McClelland RS, Lingappa JR, Srinivasan S, Kinuthia J, John-Stewart GC, Jaoko W, Richardson BA, Yuhas K, Fiedler TL, Mandaliya KN, Munch MM, Mugo NR, Cohen CR, Baeten JM, Celum C, Overbaugh J, Fredricks DN.

Lancet Infect Dis. 2018 May;18(5):554-564. doi: 10.1016/S1473-3099(18)30058-6. Epub 2018 Jan 26.

13.

Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study.

Johnston C, Magaret A, Roychoudhury P, Greninger AL, Reeves D, Schiffer J, Jerome KR, Sather C, Diem K, Lingappa JR, Celum C, Koelle DM, Wald A.

PLoS Med. 2017 Dec 27;14(12):e1002475. doi: 10.1371/journal.pmed.1002475. eCollection 2017 Dec.

14.

Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy.

King CC, Ellington SR, Davis NL, Coombs RW, Pyra M, Hong T, Mugo N, Patel RC, Lingappa JR, Baeten JM, Kourtis AP; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams.

J Infect Dis. 2017 Dec 19;216(12):1534-1540. doi: 10.1093/infdis/jix550.

15.

Toll-like receptor 9 polymorphism is associated with increased Epstein-Barr virus and Cytomegalovirus acquisition in HIV-exposed infants.

Beima-Sofie K, Wamalwa D, Maleche-Obimbo E, Lingappa JR, Mackelprang R, Gantt S, John-Stewart G, Casper C, Slyker JA.

AIDS. 2018 Jan 14;32(2):267-270. doi: 10.1097/QAD.0000000000001680.

16.

Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2017 Nov 6;13(11):e1006703. doi: 10.1371/journal.ppat.1006703. eCollection 2017 Nov. Erratum in: PLoS Pathog. 2019 Feb 11;15(2):e1007588.

17.

Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents.

Johnston C, Magaret A, Roychoudhury P, Greninger AL, Cheng A, Diem K, Fitzgibbon MP, Huang ML, Selke S, Lingappa JR, Celum C, Jerome KR, Wald A, Koelle DM.

Virology. 2017 Oct;510:90-98. doi: 10.1016/j.virol.2017.06.031. Epub 2017 Jul 13.

18.

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.

Donnell D, Ramos E, Celum C, Baeten J, Dragavon J, Tappero J, Lingappa JR, Ronald A, Fife K, Coombs RW; Partners PrEP Study Team.

AIDS. 2017 Sep 10;31(14):2007-2016. doi: 10.1097/QAD.0000000000001577.

19.

Erratum to: Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment.

Patel EU, Manucci J, Kahle EM, Lingappa JR, Morrow RA, Piwowar-Manning E, James A, Maluzi KF, Cheeba MM, Gray G, Kosloff B, Delany-Moretlwe S, Inambao M, Vwalika B, Quinn TC, Laeyendecker O.

BMC Infect Dis. 2017 May 19;17(1):355. doi: 10.1186/s12879-017-2454-1. No abstract available.

20.

Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.

Patel RC, Baeten JM, Heffron R, Hong T, Davis NL, Nanda K, Coombs RW, Lingappa JR, Bukusi EA, Hurst S, Thomas KK, Kourtis AP, Mugo N; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):91-96. doi: 10.1097/QAI.0000000000001339.

21.

A cross-sectional analysis of Trichomonas vaginalis infection among heterosexual HIV-1 serodiscordant African couples.

Bochner AF, Baeten JM, Rustagi AS, Nakku-Joloba E, Lingappa JR, Mugo NR, Bukusi EA, Kapiga S, Delany-Moretlwe S, Celum C, Barnabas RV; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams.

Sex Transm Infect. 2017 Nov;93(7):520-529. doi: 10.1136/sextrans-2016-053034. Epub 2017 Apr 4.

PMID:
28377421
22.

Worldwide circulation of HSV-2 × HSV-1 recombinant strains.

Koelle DM, Norberg P, Fitzgibbon MP, Russell RM, Greninger AL, Huang ML, Stensland L, Jing L, Magaret AS, Diem K, Selke S, Xie H, Celum C, Lingappa JR, Jerome KR, Wald A, Johnston C.

Sci Rep. 2017 Mar 13;7:44084. doi: 10.1038/srep44084.

23.

Correction for Lund et al., HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2017 Jan 18;91(3). pii: e02074-16. doi: 10.1128/JVI.02074-16. Print 2017 Feb 1. No abstract available.

24.

Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.

Kourtis AP, Wiener J, King CC, Heffron R, Mugo NR, Nanda K, Pyra M, Donnell D, Celum C, Lingappa JR, Baeten JM; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):38-43.

25.

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2016 Oct 14;90(21):9855-9861. doi: 10.1128/JVI.01482-16. Print 2016 Nov 1. Erratum in: J Virol. 2017 Jan 18;91(3):.

26.

Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.

Fife KH, Mugwanya K, Thomas KK, Baeten JM, Celum C, Bukusi E, de Bruyn G, Mujugira A, Vwalika B, Wald A, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 May 15;213(10):1573-8. doi: 10.1093/infdis/jiv765. Epub 2015 Dec 23.

27.

Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.

Pattacini L, Baeten JM, Thomas KK, Fluharty TR, Murnane PM, Donnell D, Bukusi E, Ronald A, Mugo N, Lingappa JR, Celum C, McElrath MJ, Lund JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):119-28. doi: 10.1097/QAI.0000000000000919.

28.

Mutations of Conserved Residues in the Major Homology Region Arrest Assembling HIV-1 Gag as a Membrane-Targeted Intermediate Containing Genomic RNA and Cellular Proteins.

Tanaka M, Robinson BA, Chutiraka K, Geary CD, Reed JC, Lingappa JR.

J Virol. 2015 Dec 9;90(4):1944-63. doi: 10.1128/JVI.02698-15. Print 2016 Feb 15.

29.

Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment.

Patel EU, Manucci J, Kahle EM, Lingappa JR, Morrow RA, Piwowar-Manning E, James A, Maluzi KF, Cheeba MM, Gray G, Kosloff B, Delany-Moretlwe S, Inambao M, Vwalika B, Quinn TC, Laeyendecker O.

BMC Infect Dis. 2015 Sep 30;15:398. doi: 10.1186/s12879-015-1130-6. Erratum in: BMC Infect Dis. 2017 May 19;17 (1):355.

30.

Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial.

Barnabas RV, Baeten JM, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, Delany-Moretlwe S, Gray G, Rees H, Mujugira A, Ronald A, Stevens W, Kapiga S, Wald A, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 Feb 15;213(4):551-5. doi: 10.1093/infdis/jiv318. Epub 2015 Jun 8.

31.

Toll-like receptor gene variants and bacterial vaginosis among HIV-1 infected and uninfected African women.

Mackelprang RD, Scoville CW, Cohen CR, Ondondo RO, Bigham AW, Celum C, Campbell MS, Essex M, Wald A, Kiarie J, Ronald A, Gray G, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team.

Genes Immun. 2015 Jul-Aug;16(5):362-365. doi: 10.1038/gene.2015.13. Epub 2015 Apr 30.

32.

Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.

Pattacini L, Murnane PM, Baeten JM, Fluharty TR, Thomas KK, Bukusi E, Katabira E, Mugo N, Donnell D, Lingappa JR, Celum C, Marzinke M, McElrath MJ, Lund JM; Partners PrEP Study Team.

J Infect Dis. 2015 Jun 15;211(12):1943-52. doi: 10.1093/infdis/jiu815. Epub 2014 Dec 17.

33.

Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-saharan Africa.

Mackelprang RD, Carrington M, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, Fife K, Campbell MS, Kapiga S, Gao X, Mullins JI, Lingappa JR.

J Virol. 2015 Feb;89(4):2104-11. doi: 10.1128/JVI.01573-14. Epub 2014 Dec 3.

34.

Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples.

Kahle EM, Bolton M, Hughes JP, Donnell D, Celum C, Lingappa JR, Ronald A, Cohen CR, de Bruyn G, Fong Y, Katabira E, McElrath MJ, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2015 May 1;211(9):1451-60. doi: 10.1093/infdis/jiu621. Epub 2014 Nov 10.

35.

How HIV-1 Gag assembles in cells: Putting together pieces of the puzzle.

Lingappa JR, Reed JC, Tanaka M, Chutiraka K, Robinson BA.

Virus Res. 2014 Nov 26;193:89-107. doi: 10.1016/j.virusres.2014.07.001. Epub 2014 Jul 24. Review.

36.

A temporospatial map that defines specific steps at which critical surfaces in the Gag MA and CA domains act during immature HIV-1 capsid assembly in cells.

Robinson BA, Reed JC, Geary CD, Swain JV, Lingappa JR.

J Virol. 2014 May;88(10):5718-41. doi: 10.1128/JVI.03609-13. Epub 2014 Mar 12.

37.

Variants in host viral replication cycle genes are associated with heterosexual HIV-1 acquisition in Africans.

Bigham AW, Mackelprang RD, Celum C, De Bruyn G, Beima-Sofie K, John-Stewart G, Ronald A, Mugo NR, Buckingham K, Bamshad MJ, Mullins JI, McElrath MJ, Lingappa JR.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):127-34. doi: 10.1097/QAI.0000000000000113.

38.

Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.

Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSVHIV Transmission Study Team.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4. doi: 10.1097/QAI.0b013e3182a2db02. No abstract available.

39.

Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans.

Mackelprang RD, Bigham AW, Celum C, de Bruyn G, Beima-Sofie K, John-Stewart G, Ronald A, Mugo NR, Buckingham KJ, Bamshad MJ, Mullins JI, McElrath MJ, Lingappa JR.

J Infect Dis. 2014 May 15;209(10):1623-7. doi: 10.1093/infdis/jit807. Epub 2013 Dec 10.

40.

Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial.

Laeyendecker O, Kulich M, Donnell D, Komárek A, Omelka M, Mullis CE, Szekeres G, Piwowar-Manning E, Fiamma A, Gray RH, Lutalo T, Morrison CS, Salata RA, Chipato T, Celum C, Kahle EM, Taha TE, Kumwenda NI, Karim QA, Naranbhai V, Lingappa JR, Sweat MD, Coates T, Eshleman SH.

PLoS One. 2013 Nov 13;8(11):e78818. doi: 10.1371/journal.pone.0078818. eCollection 2013.

41.

Toll-like receptor variants are associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level.

Beima-Sofie KM, Bigham AW, Lingappa JR, Wamalwa D, Mackelprang RD, Bamshad MJ, Maleche-Obimbo E, Richardson BA, John-Stewart GC.

AIDS. 2013 Sep 24;27(15):2431-9. doi: 10.1097/QAD.0b013e3283629117.

42.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

43.

Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.

Pattacini L, Murnane PM, Kahle EM, Bolton MJ, Delrow JJ, Lingappa JR, Katabira E, Donnell D, McElrath MJ, Baeten JM, Lund JM.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1321-9. doi: 10.1089/AID.2013.0075. Epub 2013 Jul 30.

44.
45.

Host-rabies virus protein-protein interactions as druggable antiviral targets.

Lingappa UF, Wu X, Macieik A, Yu SF, Atuegbu A, Corpuz M, Francis J, Nichols C, Calayag A, Shi H, Ellison JA, Harrell EK, Asundi V, Lingappa JR, Prasad MD, Lipkin WI, Dey D, Hurt CR, Lingappa VR, Hansen WJ, Rupprecht CE.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E861-8. doi: 10.1073/pnas.1210198110. Epub 2013 Feb 12.

46.

Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters.

Campbell MS, Kahle EM, Celum C, Lingappa JR, Kapiga S, Mujugira A, Mugo NR, Fife KH, Mullins JI, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Apr;207(7):1166-70. doi: 10.1093/infdis/jit015. Epub 2013 Jan 11.

47.

Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission.

Murnane PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, Kiarie J, Wald A, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team.

PLoS One. 2012;7(11):e51192. doi: 10.1371/journal.pone.0051192. Epub 2012 Nov 30.

48.

An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention.

Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R, Baeten JM; Partners in Prevention HSVHIV Transmission Study and the Partners PrEP Study Teams.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47. doi: 10.1097/QAI.0b013e31827e622d.

49.

Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial.

de Bruyn G, Magaret A, Baeten JM, Lingappa JR, Ndase P, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

BMC Infect Dis. 2012 Oct 30;12:277. doi: 10.1186/1471-2334-12-277.

50.

Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.

Lingappa JR, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, de Bruyn G, Fife KH, Campbell MS, Kapiga S, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):164-71.

Supplemental Content

Loading ...
Support Center